Earlier quoted context omitted.
No, this is demonstrably wrong. Cutting $87,000 in markups from the price of $1,700 off-patent drugs does not mean "less is offered". To the contrary, far more people get access to the drug in question. It may mean that the system as a whole offers far less opportunity to predatory rent-seekers, but that's a feature, not a bug. And yes, you can very easily argue that many other costs don't add value. That's why point…
To the contrary, far more people get access to the drug in question. There are plenty of drugs you can get in the US that single payers systems simply won't cover. The Cancer Fund in the UK is a great example. NHS said "nope too expensive" to several drugs so unless the Cancer Fund pays for it, you're SOL. That's how single payer systems save money. That's why pointing to the superior overall life-expectancy in other…
The point of controlling costs is to provide incentives for developing drugs that not only work, but that do so at non-ruinous prices.